Alterity Therapeutics receives FDA meeting minutes on pathway for ATH434
Alterity Therapeutics announced that it has received the official meeting minutes from its End-of Phase-2 meeting for ATH434 in Multiple System Atrophy from the FDA. The minutes confirm the elements of the registrational Phase 3 program previously announced on June 9 and the path toward a potential new drug application